| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
As a quaternary ammonium compound, tetradecyltrimethylammonium bromide does not have specific biological receptors as its primary targets. The compound's long hydrophobic tetradecyl chain and positively charged head group allow it to interact with cell membranes and biological surfaces. Quaternary ammonium compounds are known for their antimicrobial properties, disrupting microbial cell membranes. The compound is used as a cationic surfactant, phase transfer catalyst, and antimicrobial agent. Its mechanism of action involves disruption of membrane integrity and protein denaturation. The compound forms hemimicelles and is used as a surface active aid.
|
|---|---|
| ln Vitro |
In capillary electrophoresis, tetradecyltrimethylammonium bromide (TTAB; TTABr) is being used more frequently as a surface active aid to help separate anionic species derived from acids. For optimal effects, tetradecyltrimethylammonium bromide has been found to need a minimum concentration of about 0.4 mM. This concentration has been selected because it is near the critical micelle concentration (CMC), which is thought to be necessary for the formation of "hemimicelles" on the capillary inner wall[3].
In vitro, tetradecyltrimethylammonium bromide is used as a biochemical reagent and cationic surfactant. It is used as an organic building block and surface active aid in capillary separation of acid-derived anionic species. The compound is known for its antimicrobial properties. Cellular assays typically evaluate its antimicrobial activity, membrane-disrupting effects, or cytotoxicity. The compound's surfactant properties make it valuable for various biochemical applications, including protein extraction, membrane studies, and capillary electrophoresis. The compound forms hemimicelles, which are important for its surfactant applications. |
| ln Vivo |
In vivo data for tetradecyltrimethylammonium bromide is limited, as it is primarily a research reagent and surfactant. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. Quaternary ammonium compounds are generally used as disinfectants and antiseptics rather than as systemic therapeutics. The compound's surfactant properties and membrane-disrupting activity would likely limit its systemic use. Specific in vivo data for the parent compound is not available in the public literature. The compound is not a therapeutic candidate.
|
| Enzyme Assay |
In vitro assays for tetradecyltrimethylammonium bromide typically evaluate its surfactant properties, antimicrobial activity, or membrane-disrupting effects. A standard protocol involves incubating the compound with bacterial cultures or model membranes at varying concentrations. Antimicrobial activity is assessed by measuring minimum inhibitory concentration (MIC) using broth microdilution methods. Membrane disruption is evaluated by measuring dye release from liposomes or changes in membrane permeability. The compound is dissolved in water or buffer and diluted to working concentrations. IC₅₀ or MIC values are calculated from dose-response curves. The compound's surfactant properties require careful handling and appropriate controls.
|
| Cell Assay |
Cellular assays for tetradecyltrimethylammonium bromide typically evaluate its cytotoxicity or membrane effects. A standard protocol involves culturing mammalian cell lines in growth medium at 37°C with 5% CO₂. Cells are treated with varying concentrations of the compound for 24-72 hours. Cell viability is assessed using MTT, CCK-8, or similar assays. Membrane integrity is evaluated by measuring lactate dehydrogenase release or using fluorescent membrane permeability dyes. IC₅₀ values are calculated from dose-response curves. The compound's surfactant properties require careful handling and appropriate controls.
|
| Animal Protocol |
In vivo animal studies for tetradecyltrimethylammonium bromide are not standard, as it is a research reagent and surfactant rather than a therapeutic candidate. The compound is classified for research use only and is not intended for human or veterinary applications. Any animal studies would be limited to toxicological evaluations of the compound as an industrial chemical or disinfectant. The compound's surfactant properties and membrane-disrupting activity suggest potential for irritation and toxicity. Specific in vivo protocols are not available in the public literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for tetradecyltrimethylammonium bromide is limited, as it is primarily a research reagent. The compound has a molecular weight of 336.40 g/mol and a molecular formula of C₁₇H₃₈BrN. It is a solid at room temperature and is soluble in water with almost transparency. As a quaternary ammonium compound, it is poorly absorbed orally and is primarily excreted unchanged. The compound is stored at room temperature in a cool and dark place. Specific ADME data is not available.
|
| Toxicity/Toxicokinetics |
Toxicity Summary
The CIR expert panel concluded that, under the existing methods of use and concentrations described in the safety assessment, the following ingredient is safe when formulated into a non-irritating formula: ...myristonium bromide... Safe for use in cosmetics, subject to certain conditions. Tetradecyltrimethylammonium bromide is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored in a dry, cool place away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain. |
| References |
|
| Additional Infomation |
Hexadecyltrimethylammonium bromide is an organic molecular entity.
Tetradecyltrimethylammonium bromide (TTAB, Myristyltrimethylammonium bromide, CAS 1119-97-7) is a biochemical reagent with the molecular formula C₁₇H₃₈BrN. It is a quaternary ammonium compound used as a cationic surfactant, phase transfer catalyst, and antimicrobial agent. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent. Its applications are limited to research and chemical synthesis. |
| Molecular Formula |
C17H38BRN
|
|---|---|
| Molecular Weight |
336.39
|
| Exact Mass |
335.218
|
| CAS # |
1119-97-7
|
| Related CAS # |
Tetradecyltrimethylammonium-d29 bromide;95523-73-2;Tetradecyltrimethylammonium-d38 bromide;95523-72-1
|
| PubChem CID |
14250
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
245-250 °C(lit.)
|
| LogP |
6.351
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
19
|
| Complexity |
158
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCC[N+](C)(C)C.[Br-]
|
| InChi Key |
CXRFDZFCGOPDTD-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C17H38N.BrH/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18(2,3)4;/h5-17H2,1-4H3;1H/q+1;/p-1
|
| Chemical Name |
trimethyl(tetradecyl)azanium;bromide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 125 mg/mL (371.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (148.64 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9727 mL | 14.8637 mL | 29.7274 mL | |
| 5 mM | 0.5945 mL | 2.9727 mL | 5.9455 mL | |
| 10 mM | 0.2973 mL | 1.4864 mL | 2.9727 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
